Novel Antimicrobial Biomaterials

新型抗菌生物材料

• 批准号: DP0663368
• 负责人: Prof Mark Willcox
• 金额: $ 30.48万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2006
• 资助国家: 澳大利亚
• 起止时间: 2006-04-03 至 2009-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0663368
• 关键词: Novel; Antimicrobial; Biomaterials

There is a clear need for new materials that repel bacteria. Infections associated with biomaterials incur a high cost in terms of human health and well being, but such infections also increase the burden on the health care system by extending hospital stays and significantly elevating costs. The cost of a catheter-related blood stream infection is around $50,000 for patients in intensive care units. If all medical devices are considered, the cost of related infections is then approximately $20 billion. The technology proposed here has the potential to reduce biomaterial related infection rates, improve health care and reduce health care costs.

显然需要新的材料来排斥细菌。与生物材料相关的感染在人类健康和福祉方面产生高成本，但此类感染也通过延长住院时间和显著提高成本而增加了医疗保健系统的负担。对于重症监护病房的患者来说，导管相关血流感染的费用约为50，000美元。如果考虑所有医疗设备，相关感染的成本约为200亿美元。这里提出的技术有可能降低生物材料相关的感染率，改善医疗保健并降低医疗保健成本。